Academic Section of Vascular Surgery, Department of Surgery and Cancer, Imperial College London, London, United Kingdom.
Academic Section of Vascular Surgery, Department of Surgery and Cancer, Imperial College London, London, United Kingdom.
J Vasc Surg Venous Lymphat Disord. 2021 Mar;9(2):525-535. doi: 10.1016/j.jvsv.2020.10.014. Epub 2020 Oct 31.
The ambulatory selective variceal ablation under local anesthesia (ASVAL) technique subscribes to the "ascending" theory of varicose vein etiology, which recommends primary ambulatory phlebectomy as a treatment for tributary varicosities and truncal vein incompetence. This systematic review explores the efficacy and safety of the ASVAL technique for the treatment of symptomatic varicose veins.
A comprehensive search of the Medline and Embase databases and the Cochrane Register of Controlled Trials in May 2019 revealed 11 original articles that were qualitatively reviewed. The primary outcome was the absence from recurrent varicose veins at 1-year follow-up. Secondary outcomes were resolution of great saphenous vein (GSV) reflux on duplex ultrasound, change in GSV diameter, objective and subjective clinical improvement in chronic venous disease, and patient-reported outcome measures.
A total of 2106 limbs underwent intervention in 1734 patients reported in two randomized controlled trials, one case control study, three cohort studies, and five case series. Varicosity recurrence at 1 year ranged from 0.5% to 13.5% in patients. Of 1622 limbs with diagnosed GSV incompetence before intervention, 1114 were competent at 1 year (mean, 68.2% [±12.62%]). All studies measuring GSV diameter reported statistically significant reductions in vein size.
ASVAL may be considered as a minimally invasive treatment for early stages of chronic venous disease in the presence of truncal reflux. The evidence base should be strengthened by prospective randomized controlled trials that follow standardized procedures and report according to recognized measures of quality of life alongside clinical and hemodynamic data.
局部麻醉下门诊选择性静脉曲张消融术(ASVAL)技术遵循静脉曲张病因的“上升”理论,该理论推荐原发性门诊静脉切除术作为治疗支静脉曲张和主干静脉功能不全的方法。本系统评价探讨了 ASVAL 技术治疗症状性静脉曲张的疗效和安全性。
2019 年 5 月对 Medline 和 Embase 数据库以及 Cochrane 对照试验登记册进行全面检索,定性审查了 11 篇原始文章。主要结局是在 1 年随访时无复发性静脉曲张。次要结局是双功能超声检查显示大隐静脉(GSV)反流消失、GSV 直径改变、慢性静脉疾病的客观和主观临床改善以及患者报告的结局测量。
两项随机对照试验、一项病例对照研究、三项队列研究和五项病例系列研究共报告了 1734 例患者的 2106 条肢体接受了干预。1 年内患者的静脉曲张复发率为 0.5%至 13.5%。在 1622 条术前诊断为 GSV 功能不全的肢体中,1114 条在 1 年内功能正常(平均 68.2%[±12.62%])。所有测量 GSV 直径的研究均报告静脉大小有统计学显著减小。
ASVAL 可被视为主干静脉反流存在时慢性静脉疾病早期阶段的一种微创治疗方法。应通过遵循标准化程序并根据公认的生活质量测量方法以及临床和血流动力学数据报告的前瞻性随机对照试验来加强证据基础。